Regeneron claims its single dose of antibody reduces the risk of exposure to Covid-19.
REPUBLIKA.CO.ID, NEW YORK – Pharmaceutical companies Regeneron Pharmaceuticals on Monday claimed that its single-dose blend of antibody drugs could reduce the risk of exposure to Covid-19 by up to 81.6 percent. The protection lasts for two to eight months, according to the results of the final stage of the trial.
“The test results show that the antibody drug, REGEN-CoV, has the potential to provide long-lasting immunity against Covid-19 infection, said Myron Cohen, quoted Reuters, Monday.
Cohen is leading the effort to develop monoclonal antibodies for the Covid-19 Prevention Network sponsored by the United States National Institutes of Health. Such immunity is especially important for immunocompromised people and people who don’t respond to vaccines, according to Regeneron.
The treatment had previously shown an 81.4 percent reduction in risk during the first month after it was administered. During the eight-month evaluation period, there were no hospitalized Covid-19 patients in the REGEN-CoV recipient group.
source: Antara, Reuters
– .
